A.C.-S.). The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-There is compelling evidence that the plasma apolipoprotein E (APOE) concentration, in addition to the APOE ε2/ε3/ε4 genotype, influences plasma lipoprotein levels, but the functional genetic variants influencing the plasma APOE concentration have not been identified. Approach and Results-Genome-wide association studies in 2 cohorts of healthy, middle-aged subjects identified the APOE locus as the only genetic locus showing robust associations with the plasma APOE concentration. Fine-mapping of the APOE locus confirmed that the rs7412 ε2-allele is the primary genetic variant responsible for the relationship with plasma APOE concentration. Further mapping of the APOE locus uncovered that rs769446 (−427T/C) in the APOE promoter is independently associated with the plasma APOE concentration. Expression studies in 199 human liver samples demonstrated that the rs769446 C-allele is associated with increased APOE mRNA levels (P=0.015). Transient transfection studies and electrophoretic mobility shift assays in human hepatoma HepG2 cells corroborated the role of rs769446 in transcriptional regulation of APOE. However, no relationships were found between rs769446 genotype and plasma lipoprotein levels in 2 cohorts (n=1648 and n=1039) of healthy middle-aged carriers of the APOE ε3/ε3 genotype. Conclusions-rs769446 is a functional polymorphism involved in the regulation of the plasma APOE concentration. (Arterioscler Thromb Vasc Biol. 2013;33:1063-1069.) 
A polipoprotein E (APOE) is a constituent of several different lipoprotein particles, including chylomicrons, very-low-density lipoproteins, and high-density lipoproteins. 1 APOE functions as a ligand for cell-surface receptors involved in the clearance of these lipoproteins. Single base-pair alterations at codons 112 and 158 in the fourth exon of the APOE gene give rise to 3 different alleles, designated APOE ε2, APOE ε3, and APOE ε4. These alleles encode the APOE2, APOE3, and APOE4 isoproteins, which differ in terms of their interactions with cell-surface receptors influencing the metabolism of triglyceride-rich lipoproteins. The APOE3 and APOE4 isoproteins bind with approximately equal affinity to lipoprotein receptors in the liver, whereas APOE2 binds with <2% affinity. 2 The lower binding affinity of APOE2 decreases the hepatic clearance of triglyceride-rich lipoproteins, ultimately leading to changes in plasma lipoprotein concentrations.
Numerous studies 1 have documented the role of the common APOE isoforms in influencing plasma lipoprotein concentrations and the impact of these isoforms on risk of coronary heart disease (CHD). As summarized in a recent meta-analysis, 3 the odds ratio for CHD is 0.80 (95% confidence interval, 0.70-0.90) for APOE ε2 carriers and 1.06 (95% confidence interval, 0.99-1.13) for APOE ε4 carriers as compared with subjects with APOE ε3/ε3 genotype. These observations underline the pivotal role of APOE2, and to a lesser extent that of APOE4, in the regulation of plasma lipoprotein concentrations and risk for CHD. However, there is also circumstantial evidence that variation in plasma APOE concentration influences plasma lipoprotein concentrations [4] [5] [6] [7] [8] and risk for CHD, 9, 10 independently of the effects of the common APOE isoproteins. This notion is supported by animal studies, which demonstrated that overexpression of Apoe is a cause of hypertriglyceridemia. 11 The APOE ε2/ε3/ε4 genotypes explain between 10% and 20% of the total variation of the plasma APOE concentration in the population at large. 5, 8, 12, 13 However, combined linkage and association analysis revealed that ≈80% of the total variation in plasma APOE concentration is determined by genetic factors. 14 This suggests that other, as yet unknown, genetic variants are involved in the regulation of plasma APOE concentration, in addition to the 2 single nucleotide polymorphisms (SNPs) responsible for the APOE ε2/ε3/ε4 genotypes (rs7412 and rs429358). Here, we performed genome-wide association (GWA) studies of the plasma APOE concentration in 2 cohorts of healthy, middle-aged Swedish subjects along with functional studies using human liver samples and the human hepatoma HepG2 cell line, leading to the identification of a novel, functional SNP (rs769446) in the APOE promoter, which is involved in the regulation of the plasma APOE concentration.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Relationships of Clinical and Biochemical Risk Indicators to Plasma APOE Concentration
The influence of age and sex on plasma APOE concentration was analyzed in the OLIVIA study, whereas the POLCA study consists exclusively of 50-year-old men. No significant relationship was observed between age and plasma APOE concentration in men (n=293), whereas a weak positive correlation (r=0.22; P<0.0001) was noted in women (n=298). In agreement with previous studies, 4, 15, 16 the plasma APOE concentration was significantly higher (P<0.0001) in women than in men (geometric mean±SD, 43.4±12.5 and 38.5±12.1 mg/L, respectively).
Spearman rank correlation coefficients between clinical and biochemical measurements and plasma APOE concentration are given in Table 1 . Moderate to fairly strong correlations with plasma APOE concentration were seen for the plasma triglyceride concentration followed by more modest relationships with the plasma cholesterol, APOB, and insulin levels, whereas weak relationships were observed for all other clinical and biochemical parameters tested.
GWA Studies of Plasma APOE Concentration
GWA studies of the plasma APOE concentration were performed in the POLCA study using SNP data from the Illumina 610 array and in the OLIVIA study using the SNP data from the Illumina 1M array. In both studies, the array-based genotype data were complemented with additional genotype data from TaqMan assays for SNPs in the APOE locus. As shown in Figures IA and IB in the online-only Data Supplement, comparable associations with the plasma APOE concentration were observed in both cohorts, with a clear signal in the APOE locus. A joint evaluation of the POLCA and OLIVIA studies was then performed to enhance the power of the genome-wide analyses. The strong signal in the APOE locus was further reinforced (Figure 1 ), and no evidence was found for other loci with robust associations with plasma APOE in the rest of the genome.
The gene structure and linkage disequilibrium plot of the SNPs in the APOE locus are shown in Figure 2 . The 4 independent SNPs (r 2 <0.1) that passed the threshold of genomewide significance for the plasma APOE concentration (shown with red dots in Figure 1 ) are indicated with arrows in Figure ρ indicates Spearman's rank correlation coefficient; APOB, apolipoprotein B; BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; and SBP, systolic blood pressure.
Independent Association of rs769446 With Plasma APOE Concentration
The 4 SNPs showing genome-wide significant associations with plasma APOE concentration (ie, rs769446, rs405509, rs429358, and rs7412) were further examined in multiple regression analysis using age, sex, cohort, body mass index, and triglycerides as covariates. As shown in Table 2 , 3 SNPs (the APOE promoter polymorphism rs769446 and the 2 polymorphisms [rs429358 and rs7412] responsible for the APOE ε2/ε3/ε4 genotypes) were independently associated with the plasma APOE concentration, whereas the APOE promoter polymorphism rs405509 showed no independent relationship to the plasma APOE concentration. The 3 SNPs accounted for 14.4% of the variation in plasma APOE concentration in POLCA, 25.2% in OLIVIA, and 18.7% in the combined POLCA-OLIVIA cohorts.
The relationships between the 2 polymorphisms (rs429358 and rs7412) responsible for the APOE ε2/ε3/ε4 genotypes and the plasma APOE concentration have been analyzed in several studies. [4] [5] [6] [7] [8] In agreement with these reports, it was found ( Table  3) that APOE ε2 carriers (ie, carriers of the minor allele of rs7412) had higher plasma APOE concentration as compared with subjects with APOE ε3/ε3 genotype, whereas APOE ε4 carriers (ie, carriers of the minor allele of rs429358) had lower plasma APOE concentration as compared with subjects with APOE ε3/ε3 genotype.
The relationship between the APOE promoter polymorphism rs769446 and the plasma APOE concentration was subsequently analyzed in each of the 6 APOE ε2/ε3/ε4 genotype groups. As shown in Table 3 , ≈17% of the subjects with APOE ε3/ε3 genotype were carriers of the rs769446C allele. It was, therefore, possible to evaluate the relationship between rs769446 and plasma APOE concentration in the absence of confounding effects of the rs7412 and rs429358 SNPs. As illustrated in Table 3 , the rs769446-C allele was associated with an increased plasma APOE concentration in subjects with APOE ε3/ε3 genotype (β [SE]=0.0798 [0.0227]; P=0.0005), underlining the independent nature of the effect of the rs769446 SNP on plasma APOE concentration.
Association Between rs769446 Genotype and Hepatic APOE mRNA Levels
As a first step toward the functional analysis of rs769446, we studied the association between the APOE promoter polymorphism and hepatic APOE mRNA levels in liver samples obtained from 199 patients undergoing aortic valve surgery. A graded relationship was observed between rs769446 genotype and hepatic APOE mRNA levels (ie, the minor allele of rs769446 was associated with higher APOE mRNA levels; Figure 3A ). For comparison, we analyzed the relationship between hepatic APOE mRNA levels and the rs429358 and rs7412 polymorphisms responsible for the APOE ε2/ε3/ε4 genotypes. As expected, no associations were found between the rs429358 and rs7412 SNPs and hepatic APOE mRNA levels (data not shown).
Functional Analysis of APOE Promoter SNPs
The observed association between rs769446 and hepatic APOE mRNA levels indicates that the APOE promoter polymorphism rs769446 influences the rate of transcription of APOE. Additional in vitro studies were performed that substantiate this hypothesis. In these studies, we compared rs769446 (also known as the −427T/C polymorphism) with 2 other SNPs in the APOE promoter, rs405509 and rs449647 (previously designated the −219T/G and −491A/T polymorphism), whereas all 3 SNPs have been implicated in the transcriptional regulation of APOE.
Transient transfection studies were conducted to explore the influence of the APOE promoter polymorphisms, rs405509, rs769446, and rs449647, on APOE transcription in human hepatoma cells ( Figure 3B ). HepG2 cells were transfected with minimal-promoter constructs for the 2 alleles for each SNP, and the activity of the construct harboring the minor allele (red bars) was expressed relative to the activity of the construct with the major allele (white bars). Significantly higher activities were observed for the rare rs769446-C construct as compared with the common rs769446-T construct, whereas no significant differences in promoter activity were noted when the rs405509 or the rs449647 constructs were compared.
Binding characteristics of a 30-bp DNA fragment that contained either the major T-allele or the minor C-allele of rs769446 were evaluated using nuclear extracts derived from HepG2 cells. As shown in Figure 3C , increased concentrations of a major DNA-protein complex (indicated by the arrow) were observed with increased nuclear extract concentrations. Quantitative analysis of this complex demonstrated significant differences between the rs769446-C and the rs769446-T fragments at all nuclear extract concentrations tested ( Figure  3D ). In contrast, no differences in the binding characteristics of the rs405509-T and rs405509-G fragments or the rs449647-A and rs449647-T fragments were observed (data not shown).
No Associations Between rs769446 and Plasma Lipoprotein Concentrations
The relationships between rs769446 and plasma lipoprotein concentrations were analyzed in the combined POLCA-OLIVIA-CORONA cohorts. This analysis was limited to subjects with APOE ε3/ε3 genotype to avoid the confounding effects of the rs7412 and rs429358 SNPs. No associations were observed between the rs769446 SNP and the plasma cholesterol, triglyceride, and high-density lipoprotein-cholesterol concentrations ( Table I in the online-only Data Supplement), or with the plasma APOA1, APOB, and LDL-cholesterol concentrations (data not shown). A replication analysis was performed in subjects with APOE ε3/ε3 genotype from the 60YO cohort. Again, associations were observed neither with the plasma cholesterol, triglyceride, and high-density 
Discussion
The aim of this study was to identify and characterize novel genetic variants involved in the regulation of plasma APOE concentration, in addition to the 2 SNPs responsible for the APOE ε2/ε3/ε4 genotype (rs429358 and rs7412). To this end, we used the GWA methodology, an approach that has proven to be highly efficient for the discovery of lipid-associated genetic loci in population studies. GWA analysis of plasma APOE concentration in 2 cohorts of healthy, middle-aged Swedes confirmed that the APOE locus is an important determinant of the plasma APOE concentration, accounting for ≈20% of the variation in plasma APOE concentration. However, no other genome-wide significant locus was encountered besides the APOE locus. This suggests that common genetic variants in the human genome outside the APOE locus have a modest impact on the plasma APOE level. Identification of such genetic loci will, therefore, require considerably larger discovery cohorts.
The major finding of this study is the identification of the rs769446 polymorphism in the APOE promoter as an independent determinant of plasma APOE concentration. The significance of this SNP was uncovered as a result of detailed statistical evaluation of SNPs in the APOE locus, after finemapping and imputation analysis. The functional relevance of rs769446 was demonstrated by expression studies in 199 human liver samples, which revealed a graded association between the rs769446 T/T, T/C, and C/C genotypes and hepatic APOE mRNA levels, by transfection studies that provided evidence for an increased basal transcription rate of the rs769446-C allele as compared with the rs769446-T allele and by electrophoretic mobility shift assay studies that showed a distinct difference in binding of nuclear factors between 30-bp fragments containing either the rs769446-C site or the rs769446-T site. It seems reasonable to assume that these observations are interrelated and part of a sequence of events starting at the level of the APOE promoter and ultimately leading to increased plasma APOE concentration. We thus propose that the minor allele of rs769446 affects the binding of hepatic nuclear factor(s) to the APOE promoter, resulting in enhanced transcription of APOE and increased APOE mRNA levels, ultimately leading to higher plasma APOE concentrations. Whereas it should be emphasized that several components of this hypothesis have not been tested experimentally, this working model is compatible with all data presented in this report.
The independent role of rs769446 in the regulation of the plasma APOE concentration was confirmed by the results from the population studies. A significant, positive relationship between rs769446 and the plasma APOE concentration was observed in subjects with the APOE ε3/ε3 genotype, in line with the data from the functional studies. This observation made it possible to test the hypothesis that variation in plasma APOE concentration influences plasma lipoprotein concentrations, as previously proposed on the basis of human population studies [5] [6] [7] [8] and the analysis of the Apoe transgenic mouse. 11 Surprisingly, no associations were found between the rs769446 SNP and plasma lipoprotein levels in subjects with the APOE ε3/ε3 genotype. It is noteworthy in this context that the earlier human studies were conducted in relatively small, heterogeneous samples, whereas in the present report the genotype-lipoprotein phenotype question was addressed using large cohorts of subjects with the APOE ε3/ε3 genotype. We therefore conclude that variation in the plasma APOE concentration does not influence plasma lipoprotein concentrations in healthy, middle-aged subjects. As a consequence, it seems unlikely that variation in plasma APOE level is of importance for CHD risk in apparently healthy individuals, but this hypothesis remains to be tested experimentally.
Previous studies reported conflicting results regarding the associations between the APOE promoter SNPs rs405509, rs769446, and rs449647 (also known as the −219G/T, −427T/ C, and −491A/T polymorphisms) 17 and the plasma APOE concentration 7, 18, 19 and risk for CHD. [18] [19] [20] More recently, it was proposed that polymorphisms in the downstream hepatic control region 2 of APOE 21 and LRP/APOER2 22 influence the plasma APOE concentration. However, in the present study, we found no evidence for the involvement of other SNPs in the APOE locus in the regulation of the plasma APOE concentration, in addition to the rs769446, rs7412, and rs429358 SNPs. These discrepancies are presumably related to the small number of SNPs and the relatively modest size of the cohorts used in the published association studies as compared with the number of SNPs analyzed and the size of the cohorts used in the present study. Nevertheless, in our initial analysis, we identified a fourth, apparently independent SNP (APOE promoter polymorphism rs405509) that passed the threshold of genome-wide significance. However, rs405509 showed no independent association with the plasma APOE concentration in multiple regression analysis. Moreover, in contrast to an earlier report from Artiga et al, 17 functional studies provided no evidence for a role of rs405509 in the regulation of the plasma APOE concentration. These observations underline the importance of a combination of functional analysis and population studies for the identification of functional genetic variants.
APOE is a multifunctional protein with an established role not only in plasma lipoprotein metabolism but also in Alzheimer disease. It is generally assumed that these distinct functions of APOE are related to the different tissues involved in these processes, the liver and the brain. It was reported by Artiga et al 23 that the minor allele of rs769446 was associated with Alzheimer disease, independent from the association between the APOE ε4 genotype and Alzheimer disease. Functional studies demonstrated that the APOE promoter polymorphisms rs769446 (−427T/C) and rs449647 (−491A/T) influenced the expression of APOE in U87 human astrocytoma cells. 23 The 2-site haplotype with the highest transcriptional activity in U87 cells contained the minor allele of rs769446, supporting the notion that rs769446 is primarily responsible for the association with Alzheimer disease. Moreover, electrophoretic mobility shift assay studies demonstrated altered protein-binding characteristics when the 2 alleles of rs769446 were evaluated with nuclear extracts derived from U87 cells. 23 Thus, the rs769446 polymorphism plays a comparable role in astrocytoma U87 cells 23 as in hepatoma HepG2 cells (this study), underlining the similarities in transcriptional regulation of APOE in brain and liver.
In conclusion, this report identified the APOE promoter polymorphism rs769446 as a functional SNP involved in the regulation of the plasma APOE concentration. However, the rs769446 SNP was not associated with changes in plasma lipoprotein levels, indicating that variation in plasma APOE concentration does not influence CHD risk.
Three common isoproteins of apolipoprotein E (APOE), designated E2, E3, and E4, influence plasma lipoprotein concentrations and the risk of coronary heart disease. However, there is circumstantial evidence that variation in plasma APOE concentration also influences plasma lipoprotein concentrations and coronary heart disease risk, independently of the effects of the common APOE isoproteins. Here, we performed genome-wide association studies of the plasma APOE concentration in healthy, middle-aged Swedish subjects along with functional studies using human liver samples and the human hepatoma HepG2 cell line, leading to the identification of a novel, functional single nucleotide polymorphism (rs769446) in the APOE promoter, which is involved in the regulation of the plasma APOE concentration independent from the APOE2 and APOE4 isoproteins. However, the rs769446 SNP was not associated with changes in plasma lipoprotein levels, indicating that variation in plasma APOE concentration does not influence coronary heart disease risk.
Significance
